Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1993;88:1588-1601

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serruys, P. W.
Right arrow Articles by Liberman, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serruys, P. W.
Right arrow Articles by Liberman, H.

Circulation, Vol 88, 1588-1601, Copyright © 1993 by American Heart Association


ARTICLES

Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial

PW Serruys, W Klein, JP Tijssen, W Rutsch, GR Heyndrickx, H Emanuelsson, SG Ball, O Decoster, E Schroeder and H Liberman
Catheterization Laboratory, Thoraxcenter, Rotterdam, The Netherlands.

BACKGROUND. Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the mitogenic effect of serotonin on vascular smooth muscle cells. METHODS AND RESULTS. We conducted a randomized, double blind, placebo-controlled trial to assess the effect of ketanserin in restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). Patients received either ketanserin (loading dose, 40 mg 1 hour before PTCA; maintenance dose, 40 mg bid for 6 months) or matched placebo. In addition, all patients received aspirin for 6 months. Coronary angiograms before PTCA, after PTCA, and at 6 months were quantitatively analyzed. Six hundred fifty-eight patients were entered into the intention-to-treat analysis. The primary clinical end point of the study was the occurrence between PTCA and 6 months of any one of the following: cardiac death, myocardial infarction, the need for repeat angioplasty, or bypass surgery. It also included the need for revascularization actuated by findings at 6-month follow-up angiography. The primary clinical end point was reached by 92 (28%) patients in the ketanserin group and 104 (32%) in the placebo group (RR, 0.89; 95% CI, 0.70, 1.13; P = .38). Quantitative angiography after PTCA and at follow-up was available in 592 patients (ketanserin, 287; control, 305). The mean difference in minimal lumen diameter between post-PTCA and follow-up angiogram (primary angiographic end point) was 0.27 +/- 0.49 mm in the ketanserin group and 0.24 +/- 0.52 mm in the control group (difference, 0.03 mm; 95% CI, -0.05, 0.11; P = .50). CONCLUSIONS. Ketanserin at the dose administered in this trial failed to reduce the loss in minimal lumen diameter during follow-up after PTCA and did not significantly improve the clinical outcome.


This article has been cited by other articles:


Home page
ChestHome page
R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington
The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 776S - 814S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz
Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 576S - 599S.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
A. F. Le Blanche, M. Bonneau, M. Wassef, M.-T. Farres, L. Gabez, B. Aubert, M. Duriez, B. I. Levy, J.-M. Bigot, and F. Boudghene
Histomorphometric Evaluation of 198Au Endovascular Brachytherapy in a Renal Artery Restenosis Model in Rabbits
Am. J. Roentgenol., September 1, 2002; 179(3): 611 - 618.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. Mercado, E. Boersma, W. Wijns, B. J. Gersh, C. A. Morillo, V. de Valk, G.-A. van Es, D. E. Grobbee, and P. W. Serruys
Clinical and quantitative coronary angiographic predictors of coronary restenosis: A comparative analysis from the balloon-to-stent era
J. Am. Coll. Cardiol., September 1, 2001; 38(3): 645 - 652.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al.
ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions
J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M.Y Salame, S Verheye, I.R Crocker, N.A.F Chronos, K.A Robinson, and S.B King III
Intracoronary radiation therapy
Eur. Heart J., April 2, 2001; 22(8): 629 - 647.
[PDF]


Home page
ChestHome page
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger
Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
Chest, January 1, 2001; 119(1_suppl): 321S - 336S.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Sabate, M. A. Costa, K. Kozuma, I. P. Kay, C. J. van der Wiel, V. Verin, W. Wijns, P. W. Serruys, and on behalf of the Dose Finding Study Group
Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy
J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1536 - 1541.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A G Violaris, A Thury, E Regar, R Melkert, and P W Serruys
Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty
Heart, September 1, 2000; 84(3): 299 - 306.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Vikenes, M. Farstad, and J. E. Nordrehaug
Serotonin Is Associated with Coronary Artery Disease and Cardiac Events
Circulation, August 3, 1999; 100(5): 483 - 489.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P.W. Serruys, D.P. Foley, G. Jackson, H. Bonnier, C. Macaya, M. Vrolix, A. Branzi, J. Shepherd, H. Suryapranata, P.J. de Feyter, et al.
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial
Eur. Heart J., January 1, 1999; 20(1): 58 - 69.
[Abstract] [PDF]


Home page
Vasc MedHome page
A. Gershlick
Endovascular manipulation to restrict restenosis
Vascular Medicine, August 1, 1998; 3(3): 177 - 188.
[Abstract] [PDF]


Home page
CirculationHome page
G. A. Stouffer, Z. Hu, M. Sajid, H. Li, G. Jin, M. T. Nakada, S. R. Hanson, and M. S. Runge
ß3 Integrins Are Upregulated After Vascular Injury and Modulate Thrombospondin- and Thrombin-Induced Proliferation of Cultured Smooth Muscle Cells
Circulation, March 10, 1998; 97(9): 907 - 915.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Pakala, J. T. Willerson, and C. R. Benedict
Effect of Serotonin, Thromboxane A2, and Specific Receptor Antagonists on Vascular Smooth Muscle Cell Proliferation
Circulation, October 7, 1997; 96(7): 2280 - 2286.
[Abstract] [Full Text]


Home page
CirculationHome page
K. G. Lehmann, R. Melkert, and P. W. Serruys
Contributions of Frequency Distribution Analysis to the Understanding of Coronary Restenosis : A Reappraisal of the Gaussian Curve
Circulation, March 15, 1996; 93(6): 1123 - 1132.
[Abstract] [Full Text]


Home page
CirculationHome page
A. G. Violaris, R. Melkert, J.-P. R. Herrman, and P. W. Serruys
Role of Angiographically Identifiable Thrombus on Long-term Luminal Renarrowing After Coronary Angioplasty : A Quantitative Angiographic Analysis
Circulation, March 1, 1996; 93(5): 889 - 897.
[Abstract] [Full Text]


Home page
CirculationHome page
S. G. Ellis, N. Omoigui, J. A. Bittl, M. Lincoff, M. W. Wolfe, G. Howell, and E. J. Topol
Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology : From a Multicenter Database of 4860 Quality-Controlled Procedures
Circulation, February 1, 1996; 93(3): 431 - 439.
[Abstract] [Full Text]


Home page
CirculationHome page
D. Zahger, M. C. Fishbein, L. I. Garfinkel, P. K. Shah, J. S. Forrester, J. Regnstrom, J. Yano, and B. Cercek
VCL, an Antagonist of the Platelet GP1b Receptor, Markedly Inhibits Platelet Adhesion and Intimal Thickening After Balloon Injury in the Rat
Circulation, September 1, 1995; 92(5): 1269 - 1273.
[Abstract] [Full Text]


Home page
CirculationHome page
A. G. Violaris, R. Melkert, and P. W. Serruys
Long-term Luminal Renarrowing After Successful Elective Coronary Angioplasty of Total Occlusions : A Quantitative Angiographic Analysis
Circulation, April 15, 1995; 91(8): 2140 - 2150.
[Abstract] [Full Text]


Home page
CirculationHome page
D. Keane, J. Haase, C. J. Slager, E. M. van Swijndregt, K. G. Lehmann, Y. Ozaki, C. di Mario, R. Kirkeeide, and P. W. Serruys
Comparative Validation of Quantitative Coronary Angiography Systems : Results and Implications From a Multicenter Study Using a Standardized Approach
Circulation, April 15, 1995; 91(8): 2174 - 2183.
[Abstract] [Full Text]


Home page
NEJMHome page
D. Tousoulis, G. Davies, P. Toutouzas, and P. Golino
Intracoronary Ketanserin after Coronary Angioplasty
N. Engl. J. Med., July 14, 1994; 331(2): 130 - 131.
[Full Text]